The oligometastatic state represents a distinct entity among those with metastatic disease and consists of patients with metastases limited in number and location, representing an intermediate state between locally confined and widely metastatic cancer. Although similar, "oligorecurrence" (limited number of metachronous metastases under conditions of a controlled primary lesion) and "oligoprogressive" (disease progression at a limited number of sites with disease controlled at other disease sites) states are distinct entities. In nonesmall cell lung cancer (NSCLC), the oligometastatic state is relatively common, with 20% to 50% of patients having oligometastatic disease at diagnosis. This subgroup of patients when receiving ablative therapy, such as surgery or stereotactic body radiation radiotherapy, can obtain markedly long progression-free and overall survival. The role of radical treatment for intracranial oligometastases is well established. Fewer data exist regarding radical treatment of extracranial metastases in lung cancer; however, retrospective series using surgery or stereotactic body radiotherapy for extracranial oligometastatic disease in NSCLC have shown excellent local control, with a suggestion of improvement in progression-free survival. In the present report, we have reviewed the data on the treatment of brain metastases in oligometastatic NSCLC and the results of ablative treatment of extracranial sites. Recently, the first randomized trial comparing ablative treatment versus control in oligometastatic disease was reported, and those data are reviewed in the context of smaller series. Finally, areas of controversy are discussed and a therapeutic approach for patients with oligometastatic disease is proposed.
Introduction
Lung cancer remains the leading cause of cancer death worldwide. According to the EUCAN, in 2012, 409,911 new cases of lung cancer were diagnosed in Europe, 1 approximately 80% of which were nonesmall cell lung cancer (NSCLC). Approximately 70% of NSCLC patients will have advanced disease at diagnosis and be considered unsuitable for curative treatment. Classically, all patients with metastatic NSCLC have been grouped in a unique category by the TNM classification under the M descriptor (stage IV). The seventh TNM classification of lung cancer proposed by the Union for International Cancer Control was the first time that the stage IV group and, therefore, the M descriptor, was subdivided into 2 categories: M1a, cases with malignant pleural or pericardial effusions and cases with nodules in the contralateral lung; and M1b, cases with distant metastases. 2 However, stages I to III were subdivided into 17 categories related to different T and N descriptors according to the prognosis. It is, therefore, striking that 70% of cases of NSCLC (approximately 230,000 in 2012) could be classified using only 2 categories according to prognosis. In the eighth edition of the TNM classification of lung cancer, the International Association for the Study of Lung Cancer (IASLC) proposed that cases of pleural or pericardial effusions, contralateral or bilateral lung nodules, contralateral or bilateral pleural nodules, or a combination of these parameters should continue to be grouped in the M1a category. However, single metastatic lesions in a single distant organ should be newly designated as M1b, and multiple lesions in a single organ or multiple lesions in multiple organs should be reclassified in a new M1c category. This is the first step toward providing a rational definition for the oligometastatic disease stage in NSCLC for the future.
representing an intermediate state between locally confined and widely metastatic cancer. The number of metastases to consider the state oligometastatic can vary and has ranged from a single metastatic lesion to a single organ with multiple metastases to multiples lesions in multiples organs. 5 However, the most accepted number of metastatic lesions to be considered oligometastatic is 5, and these should be suitable for radical treatment by local therapy (surgical resection or radiotherapy, or both) to achieve long-term survival.
The most important prognostic factor for oligometastatic disease is the status of the primary tumor. In the concept of oligometastases, the status of the primary tumor is unrestricted. However, patients with an uncontrolled primary site seem to have a worse prognosis than those with controlled primary lesions. Niibe and Hayakawa 6 proposed the concept of oligorecurrence to overcome this problem. Oligorecurrence has been defined as 1 to 5 distant metachronous metastases that can be treated by local therapy under conditions of a controlled primary lesion. Patients with oligorecurrence are considered to have a better prognosis than those with synchronous oligometastases.
Currently, oligometastatic disease comprises 4 different settings:
1. Patients with metastatic lesions limited in number and location. 4 Although a definitive number of metastasis has not been established, the most accepted is 5. The aim of treatment is to prolong progression-free survival (PFS) or achieve a cure. All the lesions, including the primary tumor, should be suitable for radical therapy. 2. Patients with multiple metastasis whose disease state is transformed to an oligometastatic disease after systemic treatment by a response such that all lesions can now be treated with radical intent. 4 This setting reflects the failure of systemic treatment to destroy 1 or a limited number of resistant clones and becomes more frequent with the use of highly effective targeted therapies. 3. Patients in whom the primary tumor and most areas of metastatic disease remain controlled but one or a limited number of metastases progress during systemic therapy. 6 Similar to the previous group is the presence of resistant clones and is observed more commonly with targeted therapies. 4. Oligorecurrence is considered present in patients who have been treated with curative intent to locoregional disease and metachronously present with 1 to 5 metastatic lesions suitable to ablative therapy. 6 The prognosis among these clinical situations is different, and each represents a heterogeneous group contingent on the number of metastatic lesions, tumor genotype (EGFR mutated, ALK rearrangements, and so forth), and type of systemic treatment. In the present review, we have focused on patients in group 1 without actionable mutations (eg, EGFR, ALK, or ROS1), although unavoidable references to the other groups will be made.
Incidence of Oligometastatic Disease
The different clinical settings defining oligometastatic disease make it difficult to know the exact incidence of this state. Most studies have used a numerical definition of 1 to 5 lesions as the cutoff and the number of organs involved (! 1). Nevertheless, oligometastases seem relatively common. A single metastasis has been reported in 7% of cases of metastatic lung cancer 7 ; however, improvements in diagnostic imagining and the introduction of positron emission tomography (PET) might better diagnose latent metastases in patients who would otherwise have been thought to have a localized disease stage. In an analysis of 725 stage IV NSCLC patients, 186 (26%) were identified with oligometastatic disease, which was defined as the presence of 5 lesions at diagnosis. Disease was confined to 1 organ site in 81% of the cases, and 51% of the patients had a single metastatic lesion. The median overall survival (OS) was longer for patients with oligometastatic disease than for patients with more lesions (17 vs. 14 months). 5 Similarly, in the proposal for M descriptors for the eighth edition of the TNM classification of lung cancer, the IASLC found 225 of the 1025 patients with metastatic disease (22%) had a single metastatic lesion and observed prognostic differences between those with multiple metastatic lesions in a single organ and those with multiple lesions in multiple organs. The most frequent site of a single lesion was bone, followed by the brain, adrenal glands, and liver. 3 
Ablative Techniques in Oligometastatic Disease
Surgical metastasectomy has been the most common option chosen as definitive therapy for the oligometastatic state (55%). 8 However, in recent years, an increasing use of less invasive ablative techniques has emerged such as stereotactic radiosurgery (SRS). SRS was first used to treat brain metastases and consists of an ablative dose of radiation to the intracranial target using multiple beams centered on the same location, which minimizes the radiation dose to any critical surrounding structures. The application of this concept to sites outside the cranium has been termed stereotactic ablative radiotherapy or stereotactic body radiotherapy (SBRT). No direct comparisons have been reported of surgery and radiotherapy as radical treatment of oligometastatic disease. Moreover, several studies included patients who underwent surgery and those receiving radiotherapy. The other ablative modalities, such as radiofrequency ablation and cryoablation, have also been used but their use is still limited. The main advantages of radiofrequency ablation is the freedom to perform the procedure regardless of any previous therapy and that it can be repeated whenever required. However, rare, but serious, complications can occur, including bronchopleural fistula, pulmonary artery pseudoaneurysm, systemic air embolism, injury of the brachial nerve and phrenic nerve, pneumonia, and needle tract seeding of the cancer. 9 
Surgery
Metastasectomy has long been used in metastatic NSCLC patients, mainly those with isolated metastases to the contralateral lung, brain, and adrenal glands. Occasionally, patients with isolated metastases in other locations (eg, bone, liver) have been treated with surgery; however, the number reported has been much smaller. In a retrospective analysis of 99 NSCLC patients with a synchronous solitary metastasis treated with curative surgery (primary tumor and metastasectomy), the 5-year OS was 38%. Favorable prognostic factors for OS were the absence of mediastinal nodal involvement
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Ablative Therapy for Oligometastatic NSCLC (median 50 vs. 19 months; P ¼ .015, in patients without or with N2-N3 involvement, respectively) and pulmonary compared with extrapulmonary metastases (5-year OS, 48.5% vs. 23.6%). 10 In another retrospective series, 22 synchronous oligometastatic NSCLC patients eligible for curative intent (metastasis limited to a single organ and all disease sites amenable to curative therapy) underwent invasive mediastinal staging before treatment. The N2-negative patients had a 5-year OS of 58%.
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Radiotherapy
Technological advances in the field of radiation oncology allow for delivery of very high radiation doses to specific sites. The use of SBRT for oligometastatic disease in the lung, liver, spine, and multiple sites reported local control rates of 70% to 90%, with grade ! 3 toxicity of < 10%. 12 Hence, this nonoperative approach has been preferred for some oligometastatic patients because of the risks of surgical morbidity and mortality, with increasing numbers of studies in this setting in recent years.
Treatment of Oligometastatic Disease by Site
Most trials of oligometastatic disease have included patients with primary tumors in locations other than NSCLC. Few studies have reported exclusively on NSCLC by the specific sites of metastases.
Oligometastasis in the Brain
Lung cancer is the main cause of brain metastases in cancer patients, representing 63% of all patients with brain metastases. 13, 14 Such metastases occur in 30% to 50% of NSCLC patients 15 and are an early event in the natural history of the cancer. Historically, brain metastases have been associated with a poor prognosis. However, in recent years, efforts have been made to more accurately categorize these patients by outcome, ranging from a median survival of 7.1 months for patients with recursive partitioning analysis (RPA) class I to 2.3 months for those with RPA class III. 16 Patients with brain metastases retain several favorable prognostic factors at diagnosis. In an analysis of 1888 patients with NSCLC and brain metastases, 43% were aged < 60 years, 85% had a Karnofsky performance status (KPS) of ! 70%, 76% had 1 to 3 brain lesions, and only one third had extracranial metastasis. 13 For years, for patients with a good KPS in whom both sites are amenable to complete resection or radiotherapy, aggressive treatment with curative intent of both the primary tumor and the brain metastases has been recommended. The European Society for Medical Oncology guidelines have recommended treatment with SRS or with either SRS or resection when a single metastasis is diagnosed for patients with RPA class I (age < 65 years, KPS ! 70%, no other cranial metastases, and a controlled primary tumor) or class II patients in the case of 2 or 3 metastases. Patients with RPA class III (KPS < 70%) should not undergo treatment owing to the dismal prognosis. 17 NSCLC patients with synchronous brain metastases who received radical treatment to the metastases and primary tumor have shown a median survival of 5.2 to 64.9 months and a 1-year OS of 22% to 95%. 15, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] When no radical treatment was administered to the primary tumor, the survival decreased (Table 1) .
We analyzed the outcomes of 54 NSCLC patients with brain metastases treated with radical intent (surgery or SBRT, or both) or palliative (whole brain radiotherapy [WBRT] or no treatment). 31 The median OS was 3 months for patients with RPA class III, 16 In another study, 42 NSCLC patients diagnosed with synchronous solitary brain metastases were treated with gamma knife SRS. However, only 26 of 42 patients (62%) received definitive thoracic therapy. All patients had a KPS score of ! 70 and 16 patients (38%) had N2-N3 nodal status. The median OS was 18 months, and the 1-, 2-and 5-year actuarial OS rate was 71.3%, 34.1%, and 21%, respectively. As expected, definitive thoracic therapy and KPS were significant prognostic factors on multivariate analysis. 27 Similar results were reported in the largest series published, in which 84 newly diagnosed NSCLC patients with synchronous solitary brain metastases were treated from December 1993 through June 2004 with craniotomy (n ¼ 53) or SRS (n ¼ 31). Forty-four patients underwent treatment of their primary lung cancer using radiotherapy or chemotherapy, or both. The 1-, 2-, 3-, and 5-year OS rates from the time of lung cancer diagnosis were 49.8%, 16.3%, 12.7%, and 7.6%, respectively. The median OS for patients stratified by thoracic stage, excluding brain metastases (stage I, II, and III) were 25.6, 9.5, and 9.9 months, respectively (P ¼ .006). The median OS was different for patients who had received treatment of primary tumors compared with those who had not (15.5 vs. 5.9 months, respectively; P ¼ .046). 26 In a series from the Dana-Farber Hospital, the data from 66 NSCLC patients with synchronous brain-only metastases treated from 2000 to 2011 were analyzed. The intrathoracic disease extent included 9 patients with stage I, 10 with stage II, and 47 with stage III. Of the 66 patients, 38 received aggressive thoracic therapy, defined as resection of the primary disease or chemoradiotherapy with a total radiation dose > 45 Gy. Aggressive thoracic treatment was associated with prolonged median OS (26.4 vs. 10.5 months; P < .001) and greater actuarial 2-year OS rates (54% vs. 26%). The benefit of aggressive thoracic therapy remained significant for patients with stage III or with multiple brain lesions. 30 A recent review of a series of patients with NSCLC and brain oligometastatic disease who had received aggressive treatment with surgery and SRS, with or without WBRT, and primary thoracic treatment has been reported. 33 Most series in which surgery was the treatment of the primary lung tumor included patients with synchronous and metachronous brain metastases. For patients treated with surgical resection of the primary lung tumor, the median OS ranged from 19 to 27 months, and the 1-and 2-year survival reached 56% to 69% and 28% to 54%, respectively. Patients who underwent aggressive radiotherapy with or without chemotherapy (generally locally advanced stages), achieved a median OS of 15.5 to 31.8 months, with 1-year survival of 50% to 71% and 2-year OS of 16% to 60%.
In conclusion, patients with NSCLC and brain-only oligometastasis represent a subgroup of patients with stage IV with better prognosis when aggressive treatment can be delivered to the primary lung tumor and metastatic site. Although N2-N3 disease is an adverse prognostic factor, chemoradiotherapy can result in a median OS of > 24 months and 3-year OS of 40%, 30 similar to that reported recently for patients with unresectable stage IIIA/IIIB. 34 
Oligometastasis in the Adrenal Glands
Draining the lung bases, the adrenal gland is a common site of metastatic disease in NSCLC. Although adrenal metastases are usually found in patients with other sites of distant metastases, the incidence of solitary metastases has been reported in 4% to 20% of those with metastatic NSCLC. 3, 35 Chemotherapy is a poor predictor of adrenal involvement, because adrenal enlargement is a benign lesion in a considerable proportion of cases. Magnetic resonance imaging and PET can be helpful in differentiating incidental benign adenomas from adrenal metastases. However, considering that the treatment and the prognosis of the patient could depend on whether the lesion is benign or malignant, histologic confirmation is recommended. 36 Traditionally, adrenalectomy (first open and, lately, laparoscopic) has been the treatment modality used in the management of adrenal metastases, although in recent years, the numbers of series reporting SBRT as curative treatment has increased.
Evidence for adrenalectomy has come from case reports or small retrospective series of cases. Only 7 reports included > 10 patients [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] (Table 2 ). Tanvetyanon et al 52 performed a systematic review of 10 studies (114 patients) to analyze the outcomes of adrenalectomy for isolated adrenal metastases in NSCLC patients in whom the primary had been treated with surgery, with an emphasis on the survival outcomes between patients with synchronous (n ¼ 48) and metachronous (n ¼ 66) metastases. The use of PET to exclude other occult metastases was only reported in 1 study. Laparoscopic adrenalectomy was used in 40% of patients. No significant difference was found in median disease-free survival was observed between synchronous (median, 11 months) or metachronous (median, 9 months) metastases. The median OS was shorter for patients with synchronous metastases than those with metachronous metastases (12 months vs. 31 months; P ¼ .029); however, the 5-year survival rates were equivalent at 26% and 25%, respectively. Recurrence at the adrenal bed or retroperitoneum occurred in 21 of 100 patients (21%). Few surgical complications developed, and no mortality was reported. Open adrenalectomy was associated with greater complications than the laparoscopic approach. Porte et al 40 included 43 patients (32 synchronous and 11 metachronous metastasis) in a retrospective review not included in the previous meta-analysis. These results, in contrast to those from the meta-analysis, did not show any differences between the recurrence or survival rates of the synchronous and metachronous groups. One of the most recent series, 46 of 37 patients with isolated adrenal metastases from NSCLC in which 20 patients underwent adrenalectomy, reported a 5-year survival of 34% in the surgical group versus 0% in the nonsurgical group. Patients did not undergo adrenalectomy because of a suspicion of N2 disease, medical comorbidities, or patient preference. On multivariate analysis, mediastinal lymph node involvement was predictive of worse 5-year survival (52% for patients without mediastinal involvement vs. 0% for those with mediastinal involvement). Ipsilateral adrenal metastasis was also predictive of 5-year survival (83% in the ipsilateral group vs. 0% in the contralateral group). It is likely that the malignancy is locally draining into the adrenal gland by way of the lymphatic channels at an early stage in development, thus explaining the ipsilateral preponderance and the better prognosis, because contralateral adrenal involvement would likely occur through hematogenous pathways. 53 Although SBRT has been most extensively studied for brain metastases and primary lung tumors, in recent years, several studies have analyzed the outcomes of SBRT to adrenal gland metastases [47] [48] [49] [50] [51] ( Table 2 ). The number of fractions (range, 3-10) and the accumulated doses (range, 10-45 Gy) varied among the studies.
Chawla et al 47 reported the first large series of SBRT for adrenal metastases. 47 In their study, the data from 30 patients with 20
adrenal metastases from the lung were analyzed. with adrenal metastases underwent SBRT (36 Gy in 3 fractions). Only 2 lesions had progressed locally, and all patients had distant failure. The actuarial 1-year disease control rate was 9%; the actuarial 1-and 2-year local control rate was 90%. Although the number of patients was small and precluded definitive conclusions, no significant differences were observed when stratified by primary site, synchronous versus metachronous, or unilateral versus bilateral disease. Thus, for adrenal oligometastatic disease, SBRT has been effectively and safely used as a noninvasive alternative to the reference standard of surgery. Despite the heterogeneity of studies reported and the lack of prospective clinical trials, relatively comparable rates of OS and local control have been obtained.
Oligometastasis in the Liver
Aggressive treatment of liver metastases from colorectal cancer is well established and has been shown to improve OS, with a 5-year survival rate of 30% to 60%. 54, 55 Liver metastases from NSCLC are less common than those to other sites, especially as a single metastatic site, and are associated with worse survival compared with other sites such as the brain or bone. [56] [57] [58] Surgery is contraindicated for most liver metastases from NSCLC because of the number, distribution, or presence of extrahepatic disease. Hence, information concerning the efficacy of liver resection for metastases from NSCLC is limited to the few reported cases and, therefore, likely to be prone to marked biases. Nevertheless, long-term survival was unexpectedly high, ranging from ! 21 to ! 60 months [59] [60] [61] [62] ( Table 3) . These results were likely influenced by careful patient selection and are unlikely to represent the general NSCLC population with liver metastases. SBRT has no strict restrictions regarding lesion location and offers the possibility of high precision noninvasive treatment, using [63] [64] [65] [66] [67] [68] [69] [70] ( Table 4) . Rusthoven et al, 67 in a multi-institutional phase I/II trial, treated 47 patients with differing malignancies and 1 to 3 hepatic metastases; 10 patients (21%) had diagnosis of lung cancer. The dose was escalated from 36 Gy (phase I) to 60 Gy (phase II) in 3 fractions. Most of the patients (69%) had received ! 1 previous systemic therapy for metastatic disease, and 45% had extrahepatic disease at study entry. The actuarial in-field local control rate at 2 years after SBRT was 92%. Among lesions with a maximal diameter of 3 cm, the 2-year local control rate was 100%. Overall, the median survival was 20.5 months. Only 1 patient experienced grade ! 3 toxicity. The lung cancer patients were included with those with ovarian and noncolorectal gastrointestinal malignancies as a group of patients with metastases from unfavorable primary sites. The median OS was 12 months. In contrast, the patients with favorable primary sites (breast, colorectal, renal, carcinoid, and gastrointestinal stromal tumors and sarcoma) had a median OS of 32 months.
In conclusion, although aggressive therapy with surgery or SBRT for oligometastatic liver disease with 1 to 3 lesions can obtain high local control and a suggestion of prolonged survival, outcomes specifically for NSCLC are markedly lacking.
Oligometastasis in the Lungs
In a Japanese study of 76 patients with resected NSCLC pulmonary metastases, the 5-year survival for patients with simultaneous metastases in the same or different lobe was 79.6% and 41.6%, respectively. 71 In patients with recurrent pulmonary metastasis, the 5-year survival was 34.8%. Multiple pulmonary metastases and mediastinal nodal metastases were identified as significant factors affecting survival. No significant difference in survival was observed between those with ipsilateral versus contralateral metastases. Similarly, in a study of surgical resection of synchronous multiple lung cancer, for those with ipsilateral (n ¼ 27) versus contralateral (n ¼ 28) disease, the 5-year survival was not significantly different between the 2 groups (27% vs. 43%). 72 Mediastinal nodal involvement was a negative prognostic factor for survival. The 5-year survival was 57% and 0% for patients without (n ¼ 25) and with (n ¼ 18) lymph node metastasis.
In another retrospective analysis of 66 patients after complete resection of synchronous pulmonary malignant lesions, the median OS was 25.4 months, and the 5-year survival rate was 38%. 73 From these findings, even patients with contralateral lung oligometastases should be considered for surgical resection, provided that no evidence is found of lymph node involvement and distant metastases after an extensive preoperative workup. Survival is much greater than that of patients assumed to have stage IV disease and treated with palliative systemic therapy. 74 Similarly, several series of patients with lung metastasis from NSCLC who underwent SBRT showed a 2-year OS rate of 33% to 84%, with local control of 51% to 96% 65, 67, [75] [76] [77] [78] [79] [80] [81] (Table 5) , reinforcing this concept.
Studies of Oligometastatic Disease
Several retrospective studies have analyzed the effect of aggressive therapy for oligometastatic disease. In this group of palliative patients, the results should be measured in terms of efficacy, such as improvements in OS and toxicity.
In a retrospective study reported in 2006, 82 23 oligometastatic NSCLC patients (1 or 2 sites) underwent aggressive therapy to the primary thoracic tumor (12 received chemoradiotherapy, 4 surgery, and 7 preoperative chemoradiotherapy followed by surgery) and distant metastases (15 with radiation or SRS, 1 with surgery, and 6 with resection followed by radiotherapy). Most of these patients had brain-only metastases (14 of 23) and stage III disease (18 of 23). The median survival of the entire group was 20 months. The median time to any recurrence was 12 months. In another retrospective study, 83 25 patients with oligometastatic NSCLC (1 to 5 lesions; median, 2) were treated to all known sites of active disease with hypofractionated image-guided radiation therapy. Most patients (92%) had extracranial oligometastatic lesions, mainly lung, lymph node, and adrenal gland lesions. The median OS and PFS were 22.7 and 7.6 months, respectively. Two patients experienced grade 3 toxicity (1 patient experienced fatigue and 1 patient developed radiation pneumonitis). More than 2 sites treated with hypofractionated image-guided radiation therapy was one of the negative prognostic factors for PFS, in addition to non-adenocarcinoma histologic type, previous systemic therapy, and progression after systemic therapy. One of the largest series comes from the MD Anderson Cancer Center. 84 In that study, 78 patients with oligometastatic NSCLC (< 5 metastases) at diagnosis underwent definitive chemoradiation therapy (! 45 Gy) to the primary site. Most had only 1 metastatic site (61 of 78), and the most common site of metastatic disease at diagnosis was the brain (42% of patients). Definitive local treatment of oligometastases was administered to 44 patients (56%). For all patients, the 2-year OS rate was 32%. OS was better for those patients who had received ! 63 Gy of radiation to the primary site, had received definitive local treatment of oligometastasis, had a KPS score > 80, and had a gross tumor volume of 124 cm 3 . Grade ! 3 pulmonary and esophageal toxicity were 6.4% and 19.4%, respectively.
Griffioen et al 85 treated 61 patients with 1 to 3 synchronous metastases with radical intent to all disease sites. In addition to the primary tumor, 50 patients had a solitary metastasis, 9 had 2 metastases, and 2 had 3 metastases. The principal location of metastases was the brain (n ¼ 36). Most patients (62%) had locally advanced (stage III) intrathoracic disease. The median OS was 13.5 months, with an actuarial 1-year OS of 54%. In our experience, 34 patients with unresectable primary NSCLC and 1 to 3 synchronous metastases were treated radically with chemoradiotherapy at the primary tumor with surgery or SBRT to the metastases. 86 Most patients had an Eastern Cooperative Oncology Group performance status of 0 to 1 (96%) and histologic subtype adenocarcinoma (65%). All patients had unresectable mediastinal involvement. The oligometastasis location was the brain (65%), lung (18%), bone (9%), and other locations (6%). Definitive treatment of the primary lung tumor was sequential chemoradiotherapy (44%) and concomitant chemoradiotherapy (52%). Treatment of metastases was SBRT (58.8%), external beam radiotherapy (23.5%), surgery (11.7%), radiofrequency ablation (2.9%), and none (2.9%). In this group of patients with a poor prognosis, the median OS was 19 months and the 1-year OS rate was 76%. 86 In a French surgical series, 87 94 NSCLC patients with extrathoracic synchronous solitary metastases underwent lung surgery with curative intent. The metastases mainly involved the brain (n ¼ 57). Sixty-nine metastases were resected. The median OS was 13 months. Metastasis resection was not a prognostic criterion on multivariate analysis.
According to these data, oligometastatic NSCLC patients treated with curative intent to their thoracic disease and distant metastases can have a median OS of > 20 months. Despite the heterogeneous population and treatment approach used in these studies, a group of stage IV patients might potentially benefit from such aggressive therapy.
Clinical Trials of Oligometastatic Disease
Few prospective trials have been conducted of oligometastatic NSCLC patients, and most have evaluated the safety and efficacy of SBRT. 67, 88, 89 The multi-institutional phase I/II study of SBRT for liver metastasis has been commented in a previous section. 67 In another dose-escalation trial to determine the maximally tolerated dose of SBRT, 61 patients with 5 metastatic lesions were included, although only 11 patients had NSCLC. 88 The 2-year OS rate for the whole population was 56.7%. For patients with 1 to 3 metastases, the 2-year OS was 60.3% compared with 21.9% for patients with 4 to 5 metastases. A prospective single-arm phase II trial examined the value of SBRT for 39 NSCLC patients with < 5 metastatic lesions amenable to local treatment (surgery or radiotherapy). 89 Of the 39 patients, 35 (87%) had a single metastatic lesion, and most of the patients had local stage III disease (74%). The brain was the most common site of metastasis (44%). The median OS was 13.5 months, and the 1-year OS was 56.4%. The median PFS was 12.1 months. Only 2 patients (5%) developed a local recurrence. The treatment was well tolerated, the transient acute esophagitis rate was 15%, and no grade ! 3 toxicity was observed with treatment of distant metastases. Recently, the first phase II randomized study of oligometastatic NSCLC was reported. 90 Seventy-four patients received front-line systemic therapy consisting of chemotherapy, EGFR tyrosine kinase inhibitors, or ALK inhibitors. Patients with 3 metastases after systemic therapy were randomized to receive local consolidation therapy (LCT) with surgery with or without radiation to the primary tumor and metastases or physician choice for standard maintenance or surveillance. The patients were balanced according to nodal status, EGFR/ALK status, response to front-line systemic therapy, the presence of brain metastases, and the number of metastases. The study was closed at the first interim analysis owing to the observed efficacy in the experimental arm after randomization of 49 patients. The study met the primary objective of 24 patients who received LCT, with a statistically significant longer median PFS (11.9 months) compared with 24 patients who not received LCT (3.9 months). A different pattern of failure was observed. Distant failure only was more frequent in the LCR arm, and locoregional or both locoregional and metastatic disease was more common in the no-LCT arm. The interval to a new site of failure was 11.9 months in the LCT arm versus 5.7 months in the no-LCR arm (P ¼ .0497). No substantial differences were found in toxicity between the 2 arms. The principal limitations of the study were the small number of patients (24 in each arm), molecular heterogeneity (including EGFR and ALK), and the definition of oligometastatic disease (after front-line systemic therapy).
Prognostic Factors
Several trials have tried to address the question of patient selection through prognostic factor identification. However, because most have been heterogeneous retrospective series composed of mixed synchronous and metachronous metastases, different thoracic stages and sites of metastases, different treatments, and variably reported oncogene status, it is difficult to draw definitive conclusions.
In the largest retrospective series from the Dana-Farber Cancer Institute, 5 Eastern Cooperative Oncology Group performance status of ! 2, nodal status N2-N3, squamous histologic type, and metastases to multiple organs were associated with shorter OS. However, the differences in the number of metastatic lesions and radiologic size of the primary were not statistically significant. Definitive local therapy to the primary tumor and to the metastatic sites was associated with prolonged survival. Ashworth et al 91 performed an individual patient data metaanalysis to determine the prognostic factors for oligometastatic NSCLC. Data were available from 757 NSCLC patients with 1 to 5 synchronous (75.5%) or metachronous (24.5%) metastases treated with surgical metastectomy, stereotactic radiotherapy or radiosurgery, or radical external beam radiotherapy and curative treatment of the primary lung cancer. The median patient age was 61.1 years, and 98.3% had good performance status. Excluding metastatic disease, 66% of the patients had intrathoracic stage I-II. Patients most commonly presented with a single synchronous metastasis located in the brain (36%) or lung (34%). Only 3% of patients had multiorgan metastatic disease. The median OS for the whole population was 26 months. On multivariate analysis, the factors predictive of OS were synchronous versus metachronous metastases, nodal stage, and adenocarcinoma histologic type. RPA was subsequently performed to stratify the patients into risk groups: low risk, metachronous metastases and stage N0 (5-year OS, 47.8%); intermediate risk, synchronous metastases and N0 disease (5-year OS, 36.2%); and high risk, synchronous metastases and N1-N2 disease (5-year OS, 13.8%). The limitations of the meta-analysis were that 96.5% of patients had 1 to 2 metastatic sites and the number of patients with ! 3 metastases was underrepresented.
Several factors have been shown to affect survival in different studies. Among the most prominent were the number of metastases and mediastinal involvement. The number of metastatic sites could be a potential predictor of survival. In an analysis from the Southwest Oncology Group of 2531 patients with advanced-stage NSCLC, 7 Mediastinal nodal involvement has been shown to be an adverse prognostic factor for survival of patients with oligometastatic disease. 10, 11, 15, 46, 71, 72, 92, 93 Despite the heterogeneity in these studies, their findings support that nodal involvement is a prognostic factor. The value of nodal status in cancer prognosis is unsurprising because it is a well-established category for the TNM classification. Recently, a review of 39,731 patients with NSCLC and M1a disease showed that M1a patients without lymph node involvement had the best survival, followed by patients with N1 disease. No difference in survival was observed between N2 and N3 disease. Multivariate analysis confirmed that lymph node involvement was an independent prognostic factor for M1a patients. 94 In conclusion, patients with good performance status, a single metastatic site, and without thoracic nodal involvement represent the group with the most favorable prognosis in oligometastatic disease and should be selected for curative ablative therapy.
Future Directions
Oligometastatic disease is a unique clinical and, likely, biologic entity observed in some patients with metastatic lung cancer. The main characteristic of the oligometastatic status is that the solitary or few metastases are amenable to localized therapy, including SBRT or resection. However, the key question is the effect of locally ablative therapies in these patients. The treatment benefit in oncology should be measured in terms of toxicity and efficacy. Studies of ablative therapies such as SBRT or surgery have reported acceptable toxicity rates. The retrospective method used in most of the reported series has made it difficult to draw definitive conclusions regarding the effectiveness of ablative therapies. Moreover, another major limitation of these series was their single-arm nature. Hence, the question that remains unanswered is whether the better outcomes have resulted from the ablative treatment or the more indolent behavior of the disease. A retrospective analysis of 90 NSCLC patients presenting with 3 metastatic lesions at diagnosis addressed the question of whether comprehensive local therapy (chemotherapy plus surgery or radiotherapy, or both) with curative intent improves the outcomes compared with less aggressive therapy, given mostly with palliative intent. Improved OS (27.1 vs. 13.1 months) and PFS (11.3 vs. 8 months) were observed in patients who had undergone comprehensive local therapy. 95 In another retrospective analysis, 78 patients with oligometastatic disease underwent definitive chemoradiation to the primary site, and most (44 of 78) also underwent localized radiotherapy to sites of oligometastases. A radiation dose of ! 63 Gy to the primary site and localized radiotherapy to all sites of oligometastases were associated with a significantly prolonged OS. 84 These findings suggest that aggressive management of local disease and limited synchronous metastases could result in improved PFS and OS. More information regarding this question has come from the unique randomized phase II trial of oligometastatic disease. 90 LCT to the primary and metastases (surgery with or without radiation) in patients with 3 lesions prolonged the median PFS by 8 months compared with no local therapy (median PFS, 3.9 months for patients without LCT vs. 11.9 months for the LCT group). Another important question that remains unanswered is which oligometastatic patients should be treated. A good performance status, single metastatic site, and N0-N1 disease are favorable prognostic factors and define a group of oligometastatic patients with prolonged disease-free survival and OS when undergoing locally ablative therapy. 5, 7, 10, 11, 15, 46, 67, 71, 72, 91, 93 In some studies, patients with synchronous metastases had a poorer prognosis than those who presented with metachronous disease. 52, 91, 96 In contrast, in other studies, no statistically significant difference was observed. 35, 49, 97 The different prognosis can be explained by the more indolent and slower growth of metachronous disease. Although the therapeutic benefit is better established in this group of good prognosis oligometastatic patients, the lack of efficacy of a comprehensive approach in patients with > 1 metastatic lesion (those with 2-5 lesions) or N2 disease has not been proved. Thus, chemotherapy for metastatic NSCLC showed an absolute improvement of 9% at 12 months, increasing survival from 20% to 29%, or an absolute increase in median survival of 1.5 months (from 4.5 to 6 months). 98 In the locally advanced NSCLC setting, concomitant chemoradiation compared with sequential chemoradiation showed an increase OS rate of 5.7% at 3 years and an increase of 4.5% at 5 years, 99 or a prolongation of median OS from 14.6 months to 17 months. 100 The discovery of sensitizing mutations in EGFR and the subsequent development of EGFR tyrosine kinase inhibitors have substantially changed the prognosis of these subgroups of NSCLC patients, showing significant improvements in PFS (median, 8-13.7 months) and OS (median, 19.3-31.6 months) compared with chemotherapy. Recently, other molecular alterations (eg, ALK, ROS1, BRAF ) have been described, and targeted therapies against them have been licensed and are being developed. However, only a small proportion of NSCLC patients present with 1 of these targetable alterations. Oligometastatic disease is diagnosed in 7% to 26% of metastatic NSCLC patients. 5, 7 Although N2-N3 disease is an adverse prognostic factor, definitive treatment with chemoradiation or surgery to the primary and metastasis can obtain a median OS of 10 to 19 months and 3-year survival of 24% to 40%. 10, 15, 26, 30, 86 The benefit of aggressive thoracic therapy compared with a more palliative approach remains significant for patients with stage III. 30 Recently, immune checkpoints inhibitors and monoclonal antibodies against programmed death receptor 1, such as nivolumab or pembrolizumab, and the programmed death ligand 1 inhibitor, atezolizumab, have demonstrated improved survival compared with chemotherapy. [101] [102] [103] [104] [105] This leads to the question of the role of immunotherapy in oligometastatic disease. Combining radiation therapy and immunotherapy is an attractive area under study.
Radiotherapy cell death can be immunogenic and can promote the production and presentation of tumor antigens, increasing the antitumor immune responses achieved by checkpoint inhibitors. SBRT seems to be the most appropriate radiotherapy, because SBRT has been shown to induce cellular expression of major histocompatibility complex I, adhesion molecules, costimulatory molecules, heat shock proteins, inflammatory mediators, immunomodulatory cytokines, and death receptors to enhance antitumor immune responses. 106 The abscopal effect, in which radiotherapy to 1 metastatic site leads to tumor regression in other sites, has been described in NSCLC patients treated with immunotherapy. 107 The synergism of SBRT and immunotherapy could be especially relevant for those with oligometastatic disease in whom the tumor burden is low. A final question is the effect of PET/computed tomography (CT) in the management of oligometastatic disease. Currently, PET/CT is recommended for staging NSCLC owing to its great sensitivity for mediastinal lymph nodes and distant metastases. 108 PET/CT will detects occult metastasis in 16% of patients for whom conventional staging methods fail. 109 Tönnies et al 92 investigated whether the use of PET/CT for preoperative staging influences survival of NSCLC patients with resected solitary metastases. A total of 66 patients underwent surgery after an initial PET/CT scan, and 115 patients underwent conventional preoperative staging by spiral CT.
The 5-year survival rates after preoperative evaluation by PET/CT and conventional CT were 58% and 33%, respectively (P ¼ .01). Hence, a careful staging workup with PET/TC and brain MRI (owing to the limitations of PET in the brain) could be critical for confirming or ruling out oligometastatic disease.
With the limitation that most of the data were from retrospective series, we propose a therapeutic approach for oligometastatic patients (Figure 1) . Ongoing trials will help us to define the best approach for this subgroup of patients.
Conclusion
Despite the heterogeneity in the definition of oligometastatic status and the retrospective method used in most studies, patients with this type of metastatic cancer with a limited number of lesions (generally 1-5) have a better prognosis than patients with polymetastatic disease. Long-term disease control, even cure, can be achieved by ablative treatment of both the primary tumor and metastases. Most lung cancer guidelines have incorporated treatment recommendations for this subgroup of patients. The European Society for Medical Oncology guidelines 110 have recommended systemic therapy and radical local treatment (high-dose radiotherapy or surgery) for stage IV patients with 1 to 3 metastases at diagnosis. The NCCN guidelines, version 3.2017, 111 have recommended aggressive local therapy to the metastatic and primary sites for patients classified as having stage M1b according to the eighth edition of the lung cancer staging system proposed by IASLC (only 1 metastatic site). Whilst patients with multiple metastatic sites, independently if they have 2 to 5 metastases, should undergo systemic treatment. In conclusion, the appropriate treatment of patients with multiple synchronous metastases remains unknown, and these patients should be included in prospective clinical trials stratified by the number of metastases (2-3 vs. [4] [5] and number of organs involved.
